<p>Prime Medicine, Inc.（纽约证券交易所代码：PRME - 获取免费报告）在目前覆盖该股票的八位分析师中被评为 “适度买入”，Marketbeat 报道。三位股票研究分析师给予该股票持有评级，四位给予买入评级，一位给予强烈买入评级。在过去一年中，覆盖该股票的经纪公司平均一年目标价为 9.2083 美元。</p>
<ul>
<li>2 只基因编辑股票值得关注，列入 2024 年观察名单</li>
</ul>
<p>多家经纪公司最近对 PRME 发表了看法。Wedbush 在 11 月 10 日的研究报告中重申了 “跑赢大盘” 的评级，并对 Prime Medicine 的股票设定了 8.00 美元的目标价。花旗集团在 11 月 11 日的研究报告中将 Prime Medicine 的目标价从 5.00 美元下调至 4.25 美元，并对该股票设定了 “中性” 评级。最后，Chardan Capital 在 11 月 10 日的报告中将 Prime Medicine 的目标价从 10.00 美元下调至 9.00 美元，并对该公司设定了 “买入” 评级。</p>
<p>获取 <strong>Prime Medicine</strong> 警报：</p>
<p><strong>阅读我们关于 PRME 的最新报告</strong></p>
<h2>Prime Medicine 价格表现</h2>
<p>纽约证券交易所 PRME 周三开盘价为 3.72 美元。该公司的 50 日移动平均价格为 4.92 美元，200 日移动平均价格为 3.65 美元。公司市值为 6.715 亿美元，市盈率为-1.81，贝塔值为 2.64。Prime Medicine 的 1 年最低价为 1.11 美元，1 年最高价为 6.94 美元。</p>
<h2>机构投资者对 Prime Medicine 的看法</h2>
<p>多家机构投资者和对冲基金最近买入和卖出了 PRME 的股票。Levin Capital Strategies L.P.在第二季度将其在 Prime Medicine 的持股增加了 300.0%。Levin Capital Strategies L.P.现在拥有 140,000 股该公司的股票，价值 346,000 美元，此前在上个季度增持了 105,000 股。Palumbo Wealth Management LLC 在第二季度将其在 Prime Medicine 的股份增加了 92.1%。Palumbo Wealth Management LLC 现在拥有 183,358 股该公司的股票，价值 453,000 美元，此前在上个季度增持了 87,896 股。Vanguard Personalized Indexing Management LLC 在第二季度将其在 Prime Medicine 的持股增加了 52.2%。Vanguard Personalized Indexing Management LLC 现在拥有 23,191 股该公司的股票，价值 57,000 美元，此前在上个季度增持了 7,954 股。Ieq Capital LLC 在第一季度购买了 Prime Medicine 的新股份，价值约 69,000 美元。最后，纽约梅隆银行在第一季度将其在 Prime Medicine 的持股增加了 20.4%。纽约梅隆银行现在拥有 155,992 股该公司的股票，价值 310,000 美元，此前在上个季度增持了 26,478 股。对冲基金和其他机构投资者持有该公司 70.37% 的股份。</p>
<h2>关于 Prime Medicine</h2>
<p>（获取免费报告）</p>
<p>Prime Medicine, Inc.是一家生物技术公司，通过部署基因编辑技术提供遗传疗法，以应对各种疾病。该公司提供 Prime Editors，包含 Cas 蛋白和逆转录酶的融合体的 Prime Editor 蛋白；以及 pegRNA，旨在将 Prime Editor 定位到特定的基因组位置，并为对目标 DNA 序列进行所需编辑提供模板。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Prime Medicine</li>
<li>在 52 周高点盈利交易股票</li>
<li>华纳兄弟出售传闻升温：投资者需要知道的事项</li>
<li>能源和石油股票解析</li>
<li>从科学项目到溶剂：WeRide 的 761% 收入激增</li>
<li>何时出售股票以获利或亏损</li>
<li>标普 500 在 12 月会反弹吗？这三个信号指向重大变动</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBSTUU?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBSTUU"/></p>
<p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Prime Medicine 吗？</h2>
<p>在考虑 Prime Medicine 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Prime Medicine 并不在名单上。</p>
<p>虽然 Prime Medicine 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRME

<p>Prime Medicine, Inc.（纽约证券交易所代码：PRME）获得了八位分析师的共识 “适度买入” 评级。该股票的 1 年目标价格平均为 9.2083 美元。最近的分析师行动包括 Wedbush 的 “跑赢大盘” 评级，目标价为 8 美元，花旗集团的 “中性” 评级，目标价为 4.25 美元，以及 Chardan Capital 的 “买入” 评级，目标价为 9 美元。机构投资者增加了持股，对冲基金持有该股票的 70.37%。Prime Medicine 专注于利用基因编辑技术进行基因疗法</p>

<p>Prime Medicine, Inc. (NYSE:PRME - Get Free Report) has been assigned a consensus rating of &#34;Moderate Buy&#34; from the eight analysts that are currently covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $9.2083.</p>
<div class="lb-trans"><p>Prime Medicine, Inc.（纽约证券交易所代码：PRME - 获取免费报告）在目前覆盖该股票的八位分析师中被评为 “适度买入”，Marketbeat 报道。三位股票研究分析师给予该股票持有评级，四位给予买入评级，一位给予强烈买入评级。在过去一年中，覆盖该股票的经纪公司平均一年目标价为 9.2083 美元。</p>
</div><ul>
<li>2 gene editing stocks to keep on your 2024 watchlist</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因编辑股票值得关注，列入 2024 年观察名单</li>
</ul>
</div><p>A number of brokerages have recently weighed in on PRME. Wedbush restated an &#34;outperform&#34; rating and issued a $8.00 price target on shares of Prime Medicine in a research report on Monday, November 10th. Citigroup lowered their price objective on shares of Prime Medicine from $5.00 to $4.25 and set a &#34;neutral&#34; rating on the stock in a research note on Tuesday, November 11th. Finally, Chardan Capital dropped their target price on shares of Prime Medicine from $10.00 to $9.00 and set a &#34;buy&#34; rating for the company in a report on Monday, November 10th.</p>
<div class="lb-trans"><p>多家经纪公司最近对 PRME 发表了看法。Wedbush 在 11 月 10 日的研究报告中重申了 “跑赢大盘” 的评级，并对 Prime Medicine 的股票设定了 8.00 美元的目标价。花旗集团在 11 月 11 日的研究报告中将 Prime Medicine 的目标价从 5.00 美元下调至 4.25 美元，并对该股票设定了 “中性” 评级。最后，Chardan Capital 在 11 月 10 日的报告中将 Prime Medicine 的目标价从 10.00 美元下调至 9.00 美元，并对该公司设定了 “买入” 评级。</p>
</div><p>Get <strong>Prime Medicine</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Prime Medicine</strong> 警报：</p>
</div><p><strong>Read Our Latest Report on PRME</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 PRME 的最新报告</strong></p>
</div><h2>Prime Medicine Price Performance</h2>
<div class="lb-trans"><h2>Prime Medicine 价格表现</h2>
</div><p>NYSE PRME opened at $3.72 on Wednesday. The business has a 50 day moving average price of $4.92 and a 200 day moving average price of $3.65. The company has a market capitalization of $671.50 million, a P/E ratio of -1.81 and a beta of 2.64. Prime Medicine has a 1-year low of $1.11 and a 1-year high of $6.94.</p>
<div class="lb-trans"><p>纽约证券交易所 PRME 周三开盘价为 3.72 美元。该公司的 50 日移动平均价格为 4.92 美元，200 日移动平均价格为 3.65 美元。公司市值为 6.715 亿美元，市盈率为-1.81，贝塔值为 2.64。Prime Medicine 的 1 年最低价为 1.11 美元，1 年最高价为 6.94 美元。</p>
</div><h2>Institutional Investors Weigh In On Prime Medicine</h2>
<div class="lb-trans"><h2>机构投资者对 Prime Medicine 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of PRME. Levin Capital Strategies L.P. raised its holdings in shares of Prime Medicine by 300.0% in the second quarter. Levin Capital Strategies L.P. now owns 140,000 shares of the company's stock worth $346,000 after acquiring an additional 105,000 shares during the last quarter. Palumbo Wealth Management LLC boosted its stake in shares of Prime Medicine by 92.1% during the second quarter. Palumbo Wealth Management LLC now owns 183,358 shares of the company's stock valued at $453,000 after acquiring an additional 87,896 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its position in Prime Medicine by 52.2% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 23,191 shares of the company's stock worth $57,000 after purchasing an additional 7,954 shares in the last quarter. Ieq Capital LLC purchased a new stake in Prime Medicine during the 1st quarter worth about $69,000. Finally, Bank of New York Mellon Corp raised its stake in Prime Medicine by 20.4% in the 1st quarter. Bank of New York Mellon Corp now owns 155,992 shares of the company's stock valued at $310,000 after purchasing an additional 26,478 shares during the last quarter. Hedge funds and other institutional investors own 70.37% of the company's stock.</p>
<div class="lb-trans"><p>多家机构投资者和对冲基金最近买入和卖出了 PRME 的股票。Levin Capital Strategies L.P.在第二季度将其在 Prime Medicine 的持股增加了 300.0%。Levin Capital Strategies L.P.现在拥有 140,000 股该公司的股票，价值 346,000 美元，此前在上个季度增持了 105,000 股。Palumbo Wealth Management LLC 在第二季度将其在 Prime Medicine 的股份增加了 92.1%。Palumbo Wealth Management LLC 现在拥有 183,358 股该公司的股票，价值 453,000 美元，此前在上个季度增持了 87,896 股。Vanguard Personalized Indexing Management LLC 在第二季度将其在 Prime Medicine 的持股增加了 52.2%。Vanguard Personalized Indexing Management LLC 现在拥有 23,191 股该公司的股票，价值 57,000 美元，此前在上个季度增持了 7,954 股。Ieq Capital LLC 在第一季度购买了 Prime Medicine 的新股份，价值约 69,000 美元。最后，纽约梅隆银行在第一季度将其在 Prime Medicine 的持股增加了 20.4%。纽约梅隆银行现在拥有 155,992 股该公司的股票，价值 310,000 美元，此前在上个季度增持了 26,478 股。对冲基金和其他机构投资者持有该公司 70.37% 的股份。</p>
</div><h2>About Prime Medicine</h2>
<div class="lb-trans"><h2>关于 Prime Medicine</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.</p>
<div class="lb-trans"><p>Prime Medicine, Inc.是一家生物技术公司，通过部署基因编辑技术提供遗传疗法，以应对各种疾病。该公司提供 Prime Editors，包含 Cas 蛋白和逆转录酶的融合体的 Prime Editor 蛋白；以及 pegRNA，旨在将 Prime Editor 定位到特定的基因组位置，并为对目标 DNA 序列进行所需编辑提供模板。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Prime Medicine</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>Warner Bros. Sale Rumors Heat Up: What Investors Need to Know</li>
<li>Energy and Oil Stocks Explained</li>
<li>From Science Project to Solvent: WeRide’s 761% Revenue Surge</li>
<li>When to Sell a Stock for Profit or Loss</li>
<li>Will the S&amp;P 500 Rally in December? These 3 Signals Point to a Big Move Ahead</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Prime Medicine</li>
<li>在 52 周高点盈利交易股票</li>
<li>华纳兄弟出售传闻升温：投资者需要知道的事项</li>
<li>能源和石油股票解析</li>
<li>从科学项目到溶剂：WeRide 的 761% 收入激增</li>
<li>何时出售股票以获利或亏损</li>
<li>标普 500 在 12 月会反弹吗？这三个信号指向重大变动</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBSTUU" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NYSE&amp;Symbol=PRME"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Prime Medicine Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Prime Medicine 吗？</h2>
</div><p>Before you consider Prime Medicine, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Prime Medicine 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Prime Medicine 并不在名单上。</p>
</div><p>While Prime Medicine currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Prime Medicine 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Prime Medicine, Inc. (NYSE:PRME) 获得分析师的平均推荐评级为 “适度买入”